SCHEMBL3658154

SCHEMBL3658154

CC(C)(C(=O)Nc1nc2ccccc2s1)S(=O)(=O)N1CCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
ADORA1 P30542 1/20 0.52
DYRK1A Q13627 1/20 0.52
SMN1; SMN2 Q16637 7/20 0.49
LMNA P02545 3/20 0.49
TP53 P04637 2/20 0.49
ALOX15 P16050 2/20 0.49
TSHR P16473 2/20 0.49
USP2 O75604 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
NPC1 O15118 7/20 0.49
RAB9A P51151 7/20 0.49
ACP1 P24666 1/20 0.49
KDM4E B2RXH2 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAPK1 P28482 2/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3661587 0.85 PDPK1 (0.56) MAPTADORA1DYRK1ASMN1; SMN2LMNA
SCHEMBL3786607 0.79 SMN1; SMN2 (0.58) MAPTADORA1SMN1; SMN2LMNANPSR1
SCHEMBL1621756 0.79 ADORA1 (0.57) MAPTADORA1DYRK1ASMN1; SMN2TSHR
SCHEMBL9891526 0.77 ADORA1 (0.69) MAPTADORA1DYRK1ASMN1; SMN2LMNA
SCHEMBL3779774 0.77 RAB9A (0.46) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL1621757 0.77 NPC1 (0.56) MAPTADORA1DYRK1ASMN1; SMN2NPC1
SCHEMBL3659566 0.77 ALDH1A1 (0.54) MAPTSMN1; SMN2LMNATSHRNPSR1
SCHEMBL3659111 0.75 NPC1 (0.59) MAPTSMN1; SMN2LMNATP53ALOX15
SCHEMBL3654247 0.75 KMT2A (0.42) MAPTSMN1; SMN2LMNATP53NPC1
SCHEMBL1464432 0.75 CNR2 (0.60) MAPTADORA1DYRK1ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US claimed
EP-2217565-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-05-22 EP claimed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US claimed
EP-2217565-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2010-08-18 EP claimed
WO-2009061652-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-14 WO claimed
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
EP-2217565-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-05-22 EP disclosed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US disclosed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US disclosed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US disclosed
WO-2009061652-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 MAPT 3638/4885ADORA1 173/4885DYRK1A 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.